Jubilant Ingrev. Q2 FY27 Earnings Call — Analysis (NSE: JUBLINGREA)
Jubilant Ingrevia reports record Q2FY27 revenue of ₹1,394 Cr (+24% YoY) and EBITDA of ₹221 Cr (+51% YoY), while announcing a strategic ₹189 Cr acquisition of a 40% stake in EMS player Zettaone Technologies.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q2FY27 Revenue ₹1,394 Cr ( +24% YoY ) . New guidance — FY27 zettaone technologies revenue g… 60% to 70% . New story: CDMO pipeline momentum and diversification .
Results
Revenue reached ₹1,394 Cr (+24% YoY); EBITDA was ₹221 Cr (+51% YoY) with PAT surging 60% YoY to ₹111 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹1,394 Cr | +24% | yoy · Q2FY27 |
| EBITDA | ₹221 Cr | +51% | yoy · Q2FY27 |
| PAT | ₹111 Cr | +60% | yoy · Q2FY27 |
| Specialty Chemicals Revenue | ₹560 Cr | +16% | yoy · Q2FY27 |
| Specialty Chemicals EBITDA | ₹140 Cr | none · Q2FY27 · 25% EBITDA margin | |
| Nutrition & Health Solutions Revenue | ₹270 Cr | +50% | yoy · Q2FY27 |
| Nutrition & Health Solutions EBITDA | ₹39 Cr | +87% | yoy · Q2FY27 · 15% EBITDA margin |
| Chemical Intermediates Revenue | ₹563 Cr | +24% | yoy · Q2FY27 |
| Chemical Intermediates EBITDA | ₹64 Cr | +26% | yoy · Q2FY27 |
| Zettaone Acquisition Outlay | ₹189 Cr | point_in_time · Q2FY27 · For 40% equity stake |
Guidance
Management expects to finish near the upper end of the ₹750–800 Cr full-year EBITDA guidance for FY27.
What management committed to
- Zettaone [Technologies] will grow by at least 60% to 70% this year [FY27]. — 60% to 70%, FY27
- At least one-third of the [CDMO] pipeline peak potential of almost INR 1,500 crore [excluding the large agro contract] will be clocked in this fiscal year [FY27]. — INR ~500 Cr (one third of 1,500 Cr), FY27
- The personal care segment slice in our overall portfolio will increase much faster and reach double digits within the next few quarters. — double-digits (>10%), H1FY28
Key themes
CDMO traction, margin expansion, and electronics entry
How the narrative shifted
- CDMO pipeline momentum and diversification: Pipeline potential was explicitly raised from the prior '>100 molecules, ₹3,500 Cr funnel' to '25+ confirmed molecules, INR 1,500 Cr peak potential ex‑big contract, INR 2,000 Cr incl. big contract', shifting the framing from broad optionality to commercial execution.
- Agro CDMO contract uncertainty hedged: Slightly shifted from 'no timeline' to 'very close to concluding' on the way forward, but still explicitly under discussion.
- Specialty mix shift toward high-margin segments: Q2 data validated the mix shift, with Specialty and Nutrition contributing 81% of quarterly EBITDA, well above the 70–80% FY27 target range.
- Acetyls recovery but structurally volatile: Core narrative shifted from solely managing volatility and recovery to actively capitalizing on European plant closures for structural market share gains.
- Capacity expansion on track: No material reframing; timeline reaffirmed and capex plan repeated.
- Geopolitical and raw material volatility: Input costs from higher crude pricing partially offset benefits, but management frames this within its normal pass‑through and diversification capabilities.
- Zettaone acquisition and semiconductor vertical integration: Entirely new narrative thread introduced this quarter, representing a major strategic pivot towards vertical integration in semiconductors.
- Personal care and consumer segment acceleration: Transitioned from a product line mention to a highlighted growth catalyst with specific trajectory guidance.
Operational commentary
- Acquisition of a 40% stake in Zettaone Technologies for ₹189 Cr to enter the electronics design and manufacturing services (EDMS) and semiconductor ecosystem.
- Gajraula multipurpose plant remains on track for commissioning by the end of the year, enhancing CDMO and fine chemicals capacity.
- European competitor plant closures in acetic anhydride present a medium-term market share gain opportunity where Jubilant currently holds high teens (~20%) share.
- Confirmed commercial pipeline stands at 25+ molecules with peak revenue potential of ~₹1,500 Cr (excluding the single large innovator CDMO contract), of which roughly one-third is expected in FY27.
- Delivered the initial contracted volume lot on the large agrochemical CDMO contract, with discussions on future volumes close to being finalized.
Analyst Q&A
Q. Expected contribution and outlook on full-year EBITDA guidance given European plant closures and large CDMO contract status?
Sticking to guidance and expecting to reach near the upper end of the ₹750-800 Cr range; European closure benefits will largely flow from early next calendar year and into FY28.
Q. What is the status and take-or-pay protection regarding future volume commitments for the large innovator CDMO contract?
The initial order has been delivered as committed; discussions around future volume scenarios are near conclusion and will be shared within a few weeks. Risk remains fully protected under contract terms.
Q. Will the European market share in acetic anhydride double, and what is the market potential?
Currently holding high teens (~20%) share in Europe and aspiring to double it over the next couple of years if competitor plant closures remain permanent.
Q. What is the timeline and conversion quantum for the 100+ molecule pipeline?
25+ molecules are confirmed with ~₹1,500 Cr peak potential (ex-large contract), with ~₹500 Cr flowing in FY27, and conversions continue dynamically every quarter.
Research and educational content only. Not investment advice.